世界の高薬理活性原薬(HPAPI)市場(~2027年):種類別(革新的、ジェネリック)、合成タイプ別(合成、バイオテクノロジー、バイオシミラー、mAb、ワクチン)、メーカー別(キャプティブ、マーチャント)、用途別(腫瘍、ホルモン不均衡、緑内障)、地域別

【英語タイトル】High Potency APIs Market/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region - Global forecast to 2027

MarketsandMarketsが出版した調査資料(PH4897-22)・商品コード:PH4897-22
・発行会社(調査会社):MarketsandMarkets
・発行日:2022年5月17日
・ページ数:270
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥984,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,206,200見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

マーケッツアンドマーケッツ社は、世界の高薬理活性原薬(HPAPI)市場規模が、2022年245億ドルから2027年396億ドルまで年平均10.1%成長すると予測しています。本調査レポートでは、高薬理活性原薬(HPAPI)の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、HPAPI分類・概要、種類別(革新的HPAPI、ジェネリックHPAPI)分析、合成タイプ別(合成、バイオテクノロジー)分析、メーカータイプ別(キャプティブ、マーチャント)分析、用途別(腫瘍、ホルモン不均衡、緑内障、その他)分析、地域別分析、競争状況、企業情報などの項目を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・HPAPI分類・概要
・世界の高薬理活性原薬(HPAPI)市場規模:種類別(革新的HPAPI、ジェネリックHPAPI)
・世界の高薬理活性原薬(HPAPI)市場規模:合成タイプ別(合成、バイオテクノロジー)
・世界の高薬理活性原薬(HPAPI)市場規模:メーカータイプ別(キャプティブ、マーチャント)
・世界の高薬理活性原薬(HPAPI)市場規模:用途別(腫瘍、ホルモン不均衡、緑内障、その他)
・世界の高薬理活性原薬(HPAPI)市場規模:地域別
・競争状況
・企業情報

“高薬理活性原薬(HPAPI)市場は、2022年245億米ドルから2027年396億米ドルまで、年平均成長率10.1%で成長すると予測”
市場を牽引するのは、がん治療薬の需要増加、抗体薬物複合体の需要拡大などです。

“革新的HPAPIセグメントが2021年に市場の最大シェアを占める見込み”
種類に基づき、HPAPI市場は革新的なものとジェネリックに区分されます。2021年にHPAPI市場で最大のシェアを占めると予想されるのは革新的セグメントです。この大きなシェアは研究開発投資の増加によるものです。

“合成APIセグメントが2021年に最大シェアを獲得”
合成の種類に基づいて、市場は合成HPAPIとバイオテクノロジーHPAPIに区分されます。2021年には合成APIセグメントが最大シェアを占める見込みです。生産が容易であること、新分子の出現、合成技術の進歩が合成HPAPIセグメントの成長を促進しています。

“腫瘍セグメントは2021年に最大シェアを占める見込み”
治療用途に基づき、市場は腫瘍、ホルモン不均衡、緑内障、その他の治療用途に分けられます。2021年には、腫瘍セグメントが市場で最大のシェアを占める見込みです。技術の進歩に加え、新たな標的治療薬の発売や、世界的な癌の有病率の増加が、腫瘍セグメントの成長を牽引しています。

“アジア地域は2022年から2027年にかけてHPAPI市場の最速成長地域”
HPAPI市場は北米、欧州、アジア、その他の地域(RoW)に区分されます。予測期間中、アジアが最も高いCAGRで成長 慢性疾患、生活習慣病、加齢に伴う疾患の有病率の高さ、ジェネリック医薬品の採用を奨励する政府の取り組みなどが、アジアの市場成長を促進する要因のひとつです。

主要製品の内訳
本調査には、部品サプライヤーからティア1企業、OEMに至るまで、さまざまな業界専門家による洞察が含まれています。
主要回答者の内訳は以下の通り:
 ・回答者別 供給側:70%、需要側:30%
 ・役職別 管理職:65%、経営幹部:25%、CXO:10%
 ・地域別 北米:25%、ヨーロッパ:20%、アジア:45%、RoW:10%

高薬理活性原薬(HPAPI)市場における主な企業は、 Pfizer, Inc. (US)、F. Hoffmann-La Roche (Switzerland)、Sanofi (France)、Bristol-Myers Squibb Company (US)、Bayer AG (Germany)、Novartis International AG (Switzerland)、Boehringer Ingelheim International GmbH. (Germany)、Teva Pharmaceutical Industries Ltd. (Israel)、Eli Lilly and Company (US)、Merck & Co., Inc. (US)、AbbVie (US)、Viatris Inc. (US)です。

調査範囲
本レポートでは、高薬理活性原薬(HPAPI)市場を地域(アジア、欧州、北米、RoW)、種類(革新的、ジェネリック)、合成タイプ(バイオテクノロジー、合成)、メーカータイプ(キャプティブ、マーチャント)、治療用途(腫瘍、ホルモン不均衡、緑内障)に基づき分類しています。また、高薬理活性原薬(HPAPI)市場における市場促進要因、機会、阻害要因、課題についても包括的にレビューしています。

レポート購入の主な利点
本レポートは、本市場における市場リーダー/新規参入者の助けとなり、高薬理活性原薬(HPAPI)市場全体とそのサブセグメントにおける収益数の最も近い近似値に関する情報を提供します。本レポートは、利害関係者が競争状況を理解し、自社のビジネスをより良く位置づけるための洞察を深め、適切な市場参入戦略を計画するのに役立ちます。また、市場の脈動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を提供します。

❖ レポートの目次 ❖

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS & EXCLUSIONS 30
1.3 STUDY SCOPE 31
1.3.1 MARKETS COVERED 31
FIGURE 1 HPAPI MARKET: GEOGRAPHIC SCOPE 32
1.3.2 YEARS CONSIDERED 32
1.4 CURRENCY 33
1.5 LIMITATIONS 33
1.6 SUMMARY OF CHANGES 33
1.7 STAKEHOLDERS 34
2 RESEARCH METHODOLOGY 35
FIGURE 2 RESEARCH DESIGN 35
2.1 SECONDARY DATA 36
2.1.1 SECONDARY SOURCES 36
2.2 PRIMARY DATA 37
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: HPAPI MARKET 37
2.2.1 KEY DATA FROM PRIMARY SOURCES 38
2.2.2 PRIMARY INSIGHTS 38
2.3 MARKET SIZE ESTIMATION 39
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 39
FIGURE 5 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 40
2.4 MARKET GROWTH RATE PROJECTIONS 40
FIGURE 6 HPAPI MARKET: CAGR PROJECTIONS 41
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 41
FIGURE 7 DATA TRIANGULATION 42
2.6 RESEARCH ASSUMPTIONS 43
2.7 RISK ANALYSIS 43
3 EXECUTIVE SUMMARY 44
FIGURE 8 HPAPI MARKET, BY TYPE, 2021 VS. 2027 44
FIGURE 9 HPAPI MARKET, BY TYPE OF MANUFACTURER, 2021 VS. 2027 45
FIGURE 10 HPAPI MARKET, BY TYPE OF SYNTHESIS, 2021 VS. 2027 46
FIGURE 11 HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2021 VS. 2027 47
FIGURE 12 GEOGRAPHIC SNAPSHOT OF HPAPI MARKET (2022–2027) 48

4 PREMIUM INSIGHTS 49
4.1 HPAPI: MARKET OVERVIEW 49
FIGURE 13 INCREASING DEMAND FOR ONCOLOGY DRUGS AND ANTIBODY-DRUG CONJUGATES TO DRIVE MARKET GROWTH 49
4.2 HPAPI MARKET, BY TYPE, (2021 VS. 2027) 50
FIGURE 14 INNOVATIVE HPAPIS TO DOMINATE THE GLOBAL MARKET IN 2027 50
4.3 HPAPI MARKET, BY TYPE OF SYNTHESIS, (2021 VS. 2027) 50
FIGURE 15 SYNTHETIC HPAPIS TO DOMINATE MARKET SHARE IN 2021 50
4.4 HPAPI MARKET BY THERAPEUTIC AREA (2021–2027) 51
FIGURE 16 ONCOLOGY SEGMENT TO REGISTER HIGHEST CAGR
DURING FORECAST PERIOD 51
4.5 GEOGRAPHICAL SNAPSHOT OF HPAPI MARKET 52
FIGURE 17 CHINA & INDIA TO REGISTER HIGH GROWTH RATES DURING 2022–2027 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 18 HPPAI MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
5.2.1 DRIVERS 54
5.2.1.1 Increasing demand for oncology drugs 54
TABLE 1 PIPELINE OF ONCOLOGY DRUGS (2021) 54
5.2.1.2 Growing demand for antibody-drug conjugates 55
5.2.1.3 Increasing focus of leading pharmaceutical companies on HPAPIs 55
5.2.1.4 Advancements in HPAPI manufacturing technologies 56
5.2.1.5 Growing focus on precision medicine 56
5.2.2 RESTRAINTS 57
5.2.2.1 Increasing requirement of large investments for employee safety 57
5.2.2.2 Discrepancies in HPAPI banding systems 57
5.2.2.3 Rising number of uncertainties associated with products 58
5.2.2.4 High risk of cross-contamination 58
5.2.3 OPPORTUNITIES 58
5.2.3.1 Growing opportunities for CMOs and CDMOs 58
5.2.3.2 Increasing opportunities for companies in emerging markets 58
5.2.4 CHALLENGES 59
5.2.4.1 Need for appropriate process designs 59
5.2.4.2 Constant evolution of industry standards and technologies 59
5.3 IMPACT OF COVID-19 ON HPAPI MARKET 59
5.4 REGULATORY ANALYSIS 60
5.4.1 HANDLING HPAPI 60
5.4.2 THIRD PARTY CERTIFICATION 61
5.4.3 CONTAINMENT STRATEGIES 61
5.4.4 CHALLENGES 62
5.5 PORTER’S FIVE FORCES ANALYSIS 62
TABLE 2 HPAPI MARKET: PORTER’S FIVE FORCES ANALYSIS 62
5.5.1 THREAT OF NEW ENTRANTS 63
5.5.2 THREAT OF SUBSTITUTES 63
5.5.3 BARGAINING POWER OF SUPPLIERS 63
5.5.4 BARGAINING POWER OF BUYERS 63
5.5.5 DEGREE OF COMPETITION 63
5.6 TECHNOLOGY ANALYSIS 63
5.6.1 HANDLING POTENT COMPOUNDS 63
5.6.2 CONTROLS 64
5.6.3 SAFETY ASSESSMENT AND STANDARD OPERATING PROCEDURES 64
5.6.4 DEDICATED EQUIPMENT AND SYSTEMS 65
5.6.5 EXPERTISE AND TRAINING 65
5.6.6 COMBUSTIBLE DUST HANDLING 65
5.6.7 SUITABLE PERSONAL PROTECTIVE EQUIPMENT 65
6 HPAPI CLASSIFICATION AND OVERVIEW 66
6.1 INTRODUCTION 66
6.2 HPAPI INGREDIENTS CLASSIFICATION AS PER SAFEBRIDGE CONSULTANTS 66
TABLE 3 CATEGORIES OF HPAPIS 66
TABLE 4 POTENCY CLASSIFICATION SYSTEM 67
7 HPAPI MARKET, BY TYPE 69
7.1 INTRODUCTION 70
FIGURE 19 INNOVATIVE HPAPIS SEGMENT TO DOMINATE HPAPI MARKET 70
TABLE 5 HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 70
7.2 INNOVATIVE HPAPIS 71
TABLE 6 INNOVATIVE HPAPIS MARKET, BY REGION, 2020–2027 (USD MILLION) 71
TABLE 7 NORTH AMERICA: INNOVATIVE HPAPIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 72
TABLE 8 EUROPE: INNOVATIVE HPAPIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 72
TABLE 9 ASIA: INNOVATIVE HPAPIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 73
7.3 GENERIC HPAPIS 73
TABLE 10 GENERIC HPAPIS MARKET, BY REGION, 2020–2027 (USD MILLION) 74
TABLE 11 NORTH AMERICA: GENERIC HPAPIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 74
TABLE 12 EUROPE: GENERIC HPAPIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 75
TABLE 13 ASIA: GENERIC HPAPIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 75

8 HPAPI MARKET, BY TYPE OF SYNTHESIS 76
8.1 INTRODUCTION 77
FIGURE 20 SYNTHETIC SEGMENT TO DOMINATE MARKET IN 2021 77
TABLE 14 HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 77
8.2 SYNTHETIC APIS 78
TABLE 15 SYNTHETIC APIS MARKET, BY REGION, 2020–2027 (USD MILLION) 78
TABLE 16 NORTH AMERICA: SYNTHETIC APIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 79
TABLE 17 EUROPE: SYNTHETIC APIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 79
TABLE 18 ASIA: SYNTHETIC APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
8.2.1 SYNTHETIC APIS MARKET, BY TYPE 80
TABLE 19 SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 80
TABLE 20 INNOVATIVE SYNTHETIC APIS 81
TABLE 21 INNOVATIVE SYNTHETIC APIS MARKET, BY REGION,
2020–2027 (USD MILLION) 81
TABLE 22 NORTH AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 23 EUROPE: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 82
TABLE 24 ASIA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 82
8.2.2 GENERIC SYNTHETIC APIS 83
TABLE 25 GENERIC SYNTHETIC APIS MARKET, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 26 NORTH AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 83
TABLE 27 EUROPE: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 84
TABLE 28 ASIA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 84
8.3 BIOTECH APIS 85
TABLE 29 BIOTECH APIS MARKET, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 30 NORTH AMERICA: BIOTECH APIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 86
TABLE 31 EUROPE: BIOTECH APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 32 ASIA: BIOTECH APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 87
8.3.1 BIOTECH APIS MARKET, BY TYPE 87
TABLE 33 BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 87
8.3.2 INNOVATIVE BIOTECH APIS 88
TABLE 34 INNOVATIVE BIOTECH APIS MARKET, BY REGION, 2020–2027 (USD MILLION) 88
TABLE 35 NORTH AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 88
TABLE 36 EUROPE: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 89
TABLE 37 ASIA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 89
8.3.3 BIOSIMILARS 90
TABLE 38 BIOSIMILARS MARKET, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 39 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 91
TABLE 40 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 41 ASIA: BIOSIMILARS INGREDIENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 92
8.3.4 BIOTECH APIS MARKET, BY PRODUCT 92
TABLE 42 BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 92
8.3.5 MONOCLONAL ANTIBODIES 93
TABLE 43 MONOCLONAL ANTIBODIES MARKET, BY REGION,
2020–2027 (USD MILLION) 93
8.3.6 VACCINES 93
TABLE 44 VACCINES MARKET, BY REGION, 2020–2027 (USD MILLION) 94
8.3.7 RECOMBINANT PROTEINS 94
TABLE 45 RECOMBINANT PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 95
9 HPAPI MARKET, BY TYPE OF MANUFACTURER 96
9.1 INTRODUCTION 97
FIGURE 21 CAPTIVE HPAPI MANUFACTURERS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2021 97
TABLE 46 HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION) 98
9.2 CAPTIVE API MANUFACTURERS 98
TABLE 47 CAPTIVE API MANUFACTURERS MARKET, BY REGION,
2020–2027 (USD MILLION) 99
TABLE 48 NORTH AMERICA: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 49 EUROPE: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 100
TABLE 50 ASIA: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 100
9.3 MERCHANT API MANUFACTURERS 101
TABLE 51 MERCHANT API MANUFACTURERS MARKET, BY REGION,
2020–2027 (USD MILLION) 101
TABLE 52 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 102
TABLE 53 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 102
TABLE 54 ASIA: MERCHANT API MANUFACTURERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 103
9.3.1 MERCHANT API MANUFACTURERS MARKET BY TYPE 103
TABLE 55 MERCHANT API MANUFACTURERS MARKET BY TYPE,
2020–2027 , (USD MILLION) 103
9.3.2 INNOVATIVE MERCHANT API MANUFACTURERS 104
TABLE 56 INNOVATIVE MERCHANT API MANUFACTURERS MARKET, BY REGION,
2020–2027 (USD MILLION) 104
TABLE 57 NORTH AMERICA: INNOVATIVE MERCHANT API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 58 EUROPE: INNOVATIVE MERCHANT API MANUFACTURERS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 59 ASIA: INNOVATIVE MERCHANT API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105
9.3.3 GENERIC MERCHANT API MANUFACTURERS 106
TABLE 60 GENERIC MERCHANT API MANUFACTURERS MARKET, BY REGION,
2020–2027 (USD MILLION) 106
TABLE 61 NORTH AMERICA: GENERIC MERCHANT API MANUFACTURERS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 62 EUROPE: GENERIC MERCHANT API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 107
TABLE 63 ASIA: GENERIC MERCHANT API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 107
9.3.4 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS 108
TABLE 64 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,
2020–2027 , (USD MILLION) 108
9.3.5 SYNTHETIC API MANUFACTURERS 108
TABLE 65 SYNTHETIC API MANUFACTURERS MARKET, BY REGION,
2020–2027 (USD MILLION) 108
TABLE 66 NORTH AMERICA: SYNTHETIC API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 67 EUROPE: SYNTHETIC API MANUFACTURERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 109
TABLE 68 ASIA: SYNTHETIC API MANUFACTURERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 110
9.3.6 BIOTECH API MANUFACTURERS 110
TABLE 69 BIOTECH API MANUFACTURERS MARKET, BY REGION,
2020–2027 (USD MILLION) 111
TABLE 70 NORTH AMERICA: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 71 EUROPE: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 112
TABLE 72 ASIA: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 112
10 HPAPI MARKET, BY THERAPEUTIC APPLICATION 113
10.1 INTRODUCTION 114
FIGURE 22 ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 114
TABLE 73 HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 115
10.2 ONCOLOGY 115
TABLE 74 HPAPI MARKET FOR ONCOLOGY, BY REGION, 2020–2027 (USD MILLION) 116
TABLE 75 NORTH AMERICA: HPAPI MARKET FOR ONCOLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 116
TABLE 76 EUROPE: HPAPI MARKET FOR ONCOLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 117
TABLE 77 ASIA: HPAPI MARKET FOR ONCOLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 117
10.3 HORMONAL IMBALANCE 118
TABLE 78 HPAPI MARKET FOR HORMONAL IMBALANCE, BY REGION,
2020–2027 (USD MILLION) 118
TABLE 79 NORTH AMERICA: HPAPI MARKET FOR HORMONAL IMBALANCE,
BY COUNTRY, 2020–2027 (USD MILLION) 119
TABLE 80 EUROPE: HPAPI MARKET FOR HORMONAL IMBALANCE, BY COUNTRY,
2020–2027 (USD MILLION) 119
TABLE 81 ASIA: HPAPI MARKET FOR HORMONAL IMBALANCE, BY COUNTRY,
2020–2027 (USD MILLION) 120
10.4 GLAUCOMA 120
TABLE 82 HPAPI MARKET FOR GLAUCOMA, BY REGION, 2020–2027 (USD MILLION) 120
TABLE 83 NORTH AMERICA: HPAPI MARKET FOR GLAUCOMA, BY COUNTRY,
2020–2027 (USD MILLION) 121
TABLE 84 EUROPE: HPAPI MARKET FOR GLAUCOMA, BY COUNTRY,
2020–2027 (USD MILLION) 121
TABLE 85 ASIA: HPAPI MARKET FOR GLAUCOMA, BY COUNTRY,
2020–2027 (USD MILLION) 122
10.5 OTHER THERAPEUTIC APPLICATIONS 122
TABLE 86 HPAPI MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION,
2020–2027 (USD MILLION) 123
TABLE 87 NORTH AMERICA: HPAPI MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 88 EUROPE: HPAPI MARKET FOR OTHER THERAPEUTIC APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 124
TABLE 89 ASIA: HPAPI MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 124
11 HPAPI MARKET, BY REGION 125
11.1 INTRODUCTION 126
TABLE 90 HPAPI MARKET, BY REGION, 2020–2027 (USD MILLION) 126
11.2 NORTH AMERICA 126
FIGURE 23 NORTH AMERICA: HPAPI MARKET SNAPSHOT 127
TABLE 91 NORTH AMERICA: HPAPI MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 128
TABLE 92 NORTH AMERICA: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 93 NORTH AMERICA: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 129
TABLE 94 NORTH AMERICA: MERCHANT APIS MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 129
TABLE 95 NORTH AMERICA: MERCHANT APIS MANUFACTURERS MARKET,
BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 130
TABLE 96 NORTH AMERICA: HPAPI MARKET, BY TYPE OF SYNTHESIS,
2020–2027 (USD MILLION) 130
TABLE 97 NORTH AMERICA: SYNTHETIC APIS INGREDIENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 131
TABLE 98 NORTH AMERICA: BIOTECH APIS MARKET, BY TYPE,
2020–2027 (USD MILLION) 131
TABLE 99 NORTH AMERICA: BIOTECH HPAPI MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 132
TABLE 100 NORTH AMERICA: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 132
11.2.1 US 133
11.2.1.1 Increasing Investments in cancer research to drive market growth 133
TABLE 101 US: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 133
TABLE 102 US: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 134
TABLE 103 US: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 104 US: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 135
TABLE 105 US: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 135
TABLE 106 US: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 107 US: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION 136
TABLE 108 US: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 137
TABLE 109 US: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 137
11.2.2 CANADA 138
11.2.2.1 The rising prevalence of cancer to drive market growth 138
TABLE 110 CANADA: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 138
TABLE 111 CANADA: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 138
TABLE 112 CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2020–2027 (USD MILLION) 139
TABLE 113 CANADA: MERCHANT API MANUFACTURERS MARKET,
BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 139
TABLE 114 CANADA: HPAPI MARKET, BY TYPE OF SYNTHESIS,
2020–2027 (USD MILLION) 140
TABLE 115 CANADA: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 116 CANADA: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 141
TABLE 117 CANADA: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 141
TABLE 118 CANADA: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 142
11.3 EUROPE 142
FIGURE 24 EUROPE: HPAPI MARKET SNAPSHOT 143
TABLE 119 EUROPE: HPAPI MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 144
TABLE 120 EUROPE: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 144
TABLE 121 EUROPE: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 145
TABLE 122 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2020–2027 (USD MILLION) 145
TABLE 123 EUROPE: MERCHANT API MANUFACTURERS MARKET,
BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 146
TABLE 124 EUROPE: HPAPI MARKET, BY TYPE OF SYNTHESIS,
2020–2027 (USD MILLION) 146
TABLE 125 EUROPE: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 126 EUROPE: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 127 EUROPE: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 148
TABLE 128 EUROPE: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 148
11.3.1 GERMANY 149
11.3.1.1 The strong focus on biotech and medical research
to drive market growth 149
TABLE 129 GERMANY: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 130 GERMANY: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 150
TABLE 131 GERMANY: MERCHANT API MANUFACTURERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 132 GERMANY: MERCHANT API MANUFACTURERS MARKET,
BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 151
TABLE 133 GERMANY: HPAPI MARKET, BY TYPE OF SYNTHESIS,
2020–2027 (USD MILLION) 151
TABLE 134 GERMANY: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 135 GERMANY: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 136 GERMANY: BIOTECH APIS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 153
TABLE 137 GERMANY: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 153
11.3.2 FRANCE 154
11.3.2.1 The presence of many pharmaceutical companies coupled with the growing demand for novel cancer therapies to drive market growth 154
TABLE 138 FRANCE: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 154
TABLE 139 FRANCE: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 154
TABLE 140 FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2020–2027 (USD MILLION) 155
TABLE 141 FRANCE: MERCHANT HPAPI MANUFACTURERS MARKET,
BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 155
TABLE 142 FRANCE: HPAPI MARKET, BY TYPE OF SYNTHESIS,
2020–2027 (USD MILLION) 156
TABLE 143 FRANCE: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 156
TABLE 144 FRANCE: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 157
TABLE 145 FRANCE: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 157
TABLE 146 FRANCE: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 158
11.3.3 UK 158
11.3.3.1 Increasing in the demand for cancer therapies to drive market growth 158
TABLE 147 UK: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 158
TABLE 148 UK: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 159
TABLE 149 UK: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2020–2027 (USD MILLION) 159
TABLE 150 UK: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 160
TABLE 151 UK: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 160
TABLE 152 UK: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 153 UK: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 154 UK: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 162
TABLE 155 UK: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 162
11.3.4 ITALY 163
11.3.4.1 Robust generic API production capacities to drive the market growth 163
TABLE 156 ITALY: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 163
TABLE 157 ITALY: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 163
TABLE 158 ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 159 ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 164
TABLE 160 ITALY: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 165
TABLE 161 ITALY: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 165
TABLE 162 ITALY: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 163 ITALY: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 166
TABLE 164 ITALY: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 167
11.3.5 SPAIN 167
11.3.5.1 Developments in the ADC segment to drive market growth 167
TABLE 165 SPAIN: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 167
TABLE 166 SPAIN: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 168
TABLE 167 SPAIN: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2020–2027 (USD MILLION) 168
TABLE 168 SPAIN: MERCHANT MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 169
TABLE 169 SPAIN: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 169
TABLE 170 SPAIN: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 170
TABLE 171 SPAIN: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 170
TABLE 172 SPAIN: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 171
TABLE 173 SPAIN: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 171
11.3.6 REST OF EUROPE 171
TABLE 174 REST OF EUROPE: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 175 REST OF EUROPE: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 172
TABLE 176 REST OF EUROPE: MERCHANT API MANUFACTURERS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 173
TABLE 177 REST OF EUROPE: MERCHANT MANUFACTURERS MARKET,
BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 173
TABLE 178 REST OF EUROPE: HPAPI MARKET, BY TYPE OF SYNTHESIS,
2020–2027 (USD MILLION) 174
TABLE 179 REST OF EUROPE: SYNTHETIC APIS MARKET, BY TYPE,
2020–2027 (USD MILLION) 174
TABLE 180 REST OF EUROPE: BIOTECH APIS MARKET, BY TYPE,
2020–2027 (USD MILLION) 175
TABLE 181 REST OF EUROPE: BIOTECH APIS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 175
TABLE 182 REST OF EUROPE: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 176
11.4 ASIA 176
FIGURE 25 ASIA: HPAPI MARKET SNAPSHOT 177
TABLE 183 ASIA: HPAPI MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 178
TABLE 184 ASIA: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 178
TABLE 185 ASIA: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 179
TABLE 186 ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2020–2027 (USD MILLION) 179
TABLE 187 ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 180
TABLE 188 ASIA: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 180
TABLE 189 ASIA: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 181
TABLE 190 ASIA: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 181
TABLE 191 ASIA: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 182
TABLE 192 ASIA: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 182
11.4.1 JAPAN 183
11.4.1.1 Investments in the development of ADC products
to drive market growth 183
TABLE 193 JAPAN: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 183
TABLE 194 JAPAN: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 183
TABLE 195 JAPAN: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2020–2027 (USD MILLION) 184
TABLE 196 JAPAN: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 184
TABLE 197 JAPAN: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 185
TABLE 198 JAPAN: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 185
TABLE 199 JAPAN: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 186
TABLE 200 JAPAN: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 186
TABLE 201 JAPAN: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 187
11.4.2 CHINA 187
11.4.2.1 Low labor costs, presence of well-equipped manufacturing plants to drive market growth 187
TABLE 202 CHINA: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 203 CHINA: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 188
TABLE 204 CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2020–2027 (USD MILLION) 188
TABLE 205 CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 189
TABLE 206 CHINA: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 189
TABLE 207 CHINA: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 190
TABLE 208 CHINA: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 190
TABLE 209 CHINA: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 191
TABLE 210 CHINA: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 191
11.4.3 INDIA 192
11.4.3.1 Increasing Investments in Oncology to drive market growth 192
TABLE 211 INDIA: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 192
TABLE 212 INDIA: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 192
TABLE 213 INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2020–2027 (USD MILLION) 193
TABLE 214 INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 193
TABLE 215 INDIA: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 194
TABLE 216 INDIA: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 217 INDIA: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 218 INDIA: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 195
TABLE 219 INDIA: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 196
11.4.4 REST OF ASIA 196
TABLE 220 REST OF ASIA: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 197
TABLE 221 REST OF ASIA: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 197
TABLE 222 REST OF ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2020–2027 (USD MILLION) 198
TABLE 223 REST OF ASIA: MERCHANT API MANUFACTURERS MARKET,
BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 198
TABLE 224 REST OF ASIA: HPAPI MARKET, BY TYPE OF SYNTHESIS,
2020–2027 (USD MILLION) 199
TABLE 225 REST OF ASIA: SYNTHETIC APIS MARKET, BY TYPE,
2020–2027 (USD MILLION) 199
TABLE 226 REST OF ASIA: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 200
TABLE 227 REST OF ASIA: BIOTECH APIS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 200
TABLE 228 REST OF ASIA: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 201
11.5 REST OF THE WORLD 201
FIGURE 26 REST OF THE WORLD: HPAPI MARKET SNAPSHOT 202
TABLE 229 ROW: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION) 202
TABLE 230 ROW: HPAPI MARKET, BY TYPE OF MANUFACTURER,
2020–2027 (USD MILLION) 203
TABLE 231 ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2020–2027 (USD MILLION) 203
TABLE 232 ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 204
TABLE 233 ROW: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 204
TABLE 234 ROW: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 205
TABLE 235 ROW: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 205
TABLE 236 ROW: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 206
TABLE 237 ROW: HPAPI MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 206
12 COMPETITIVE LANDSCAPE 207
12.1 OVERVIEW 207
12.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN 207
FIGURE 27 KEY DEVELOPMENTS IN HPAPI MARKET, 2019–2022 207
12.3 MARKET SHARE ANALYSIS 208
FIGURE 28 HPAPI MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021 208
TABLE 238 HPAPI MARKET: DEGREE OF COMPETITION 208
12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 209
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN HPAPI MARKET, 2019–2021 209
12.5 COMPANY EVALUATION QUADRANT 210
12.5.1 STARS 210
12.5.2 EMERGING LEADERS 210
12.5.3 PERVASIVE PLAYERS 210
FIGURE 30 HPAPI MARKET: COMPANY EVALUATION QUADRANT 211
12.6 FOOTPRINT OF COMPANIES 212
TABLE 239 PORTFOLIO ANALYSIS BY TYPE OF SYNTHESIS: HPAPI MARKET (2021) 212
TABLE 240 PORTFOLIO ANALYSIS BY TYPE OF MANUFACTURER: HPAPI MARKET (2021) 212
TABLE 241 PORTFOLIO ANALYSIS BY TYPE OF THERAPEUTIC APPLICATIONS: HPAPI MARKET (2021) 213
12.7 REGIONAL FOOTPRINT 214
TABLE 242 REGIONAL FOOTPRINT OF COMPANIES: HPAPI MARKET (2021) 214
12.8 COMPETITIVE SCENARIO 215
TABLE 243 PRODUCT LAUNCHES 215
TABLE 244 DEALS 216

13 COMPANY PROFILES 217
13.1 MAJOR PLAYERS 217
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 PFIZER INC. 217
TABLE 245 PFIZER INC.: BUSINESS OVERVIEW 217
FIGURE 31 PFIZER INC.: COMPANY SNAPSHOT (2021) 218
13.1.2 NOVARTIS INTERNATIONAL AG 224
TABLE 246 NOVARTIS INTERNATIONAL AG: BUSINESS OVERVIEW 224
FIGURE 32 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2021) 225
13.1.3 SANOFI 228
TABLE 247 SANOFI: BUSINESS OVERVIEW 228
FIGURE 33 SANOFI: COMPANY SNAPSHOT (2021) 229
13.1.4 F. HOFFMANN-LA ROCHE 235
TABLE 248 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW 235
FIGURE 34 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021) 236
13.1.5 BRISTOL-MYERS SQUIBB COMPANY 242
TABLE 249 BRISTOL-MYERS SQUIBB COMPANY: BUSINESS OVERVIEW 242
FIGURE 35 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2021) 242
13.1.6 BOEHRINGER-INGELHEIM 245
TABLE 250 BOEHRINGER-INGELHEIM: BUSINESS OVERVIEW 245
FIGURE 36 BOEHRINGER-INGELHEIM: COMPANY SNAPSHOT (2021) 246
13.1.7 TEVA PHARMACEUTICAL INDUSTRY LTD. 249
TABLE 251 TEVA PHARMACEUTICAL INDUSTRY LTD.: BUSINESS OVERVIEW 249
FIGURE 37 TEVA PHARMACEUTICAL INDUSTRY LTD.: COMPANY SNAPSHOT (2021) 249
13.1.8 ELI LILY AND COMPANY 253
TABLE 252 ELI LILY AND COMPANY: BUSINESS OVERVIEW 253
FIGURE 38 ELI LILY AND COMPANY: COMPANY SNAPSHOT (2021) 253
13.1.9 MERCK & CO., INC. 257
TABLE 253 MERCK & CO., INC.: BUSINESS OVERVIEW 257
FIGURE 39 MERCK & CO., INC.: COMPANY SNAPSHOT (2021) 258
13.1.10 ABBVIE INC. 262
TABLE 254 ABBVIE INC.: BUSINESS OVERVIEW 262
FIGURE 40 ABBVIE INC.: COMPANY SNAPSHOT (2021) 263
13.1.11 VIATRIS INC. 267
TABLE 255 VIATRIS INC.: BUSINESS OVERVIEW 267
FIGURE 41 VIATRIS INC.: COMPANY SNAPSHOT (2021) 268
13.1.12 BAYER 270
TABLE 256 BAYER AG: BUSINESS OVERVIEW 270
FIGURE 42 BAYER AG: COMPANY SNAPSHOT (2021) 271
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 273
14.1 DISCUSSION GUIDE 273
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 276
14.3 AVAILABLE CUSTOMIZATIONS 278
14.4 RELATED REPORTS 278
14.5 AUTHOR DETAILS 279



★調査レポート[世界の高薬理活性原薬(HPAPI)市場(~2027年):種類別(革新的、ジェネリック)、合成タイプ別(合成、バイオテクノロジー、バイオシミラー、mAb、ワクチン)、メーカー別(キャプティブ、マーチャント)、用途別(腫瘍、ホルモン不均衡、緑内障)、地域別] (コード:PH4897-22)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の高薬理活性原薬(HPAPI)市場(~2027年):種類別(革新的、ジェネリック)、合成タイプ別(合成、バイオテクノロジー、バイオシミラー、mAb、ワクチン)、メーカー別(キャプティブ、マーチャント)、用途別(腫瘍、ホルモン不均衡、緑内障)、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆